

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 November 2024 (28.11.2024)



(10) International Publication Number
WO 2024/243600 A3

(51) International Patent Classification:

A61K 31/395 (2006.01) C07D 403/04 (2006.01)
A61K 31/42 (2006.01) C07B 59/00 (2006.01)
C07D 403/02 (2006.01) A61K 31/33 (2006.01)

(21) International Application Number:

PCT/US2024/031316

(22) International Filing Date:

28 May 2024 (28.05.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/504,306	25 May 2023 (25.05.2023)	US
63/578,804	25 August 2023 (25.08.2023)	US
63/540,277	25 September 2023 (25.09.2023)	US
63/556,028	21 February 2024 (21.02.2024)	US

(71) Applicant: MAPLIGHT THERAPEUTICS, INC.

[US/US]; 800 Chesapeake Drive, Redwood City, California 94063 (US).

(72) Inventors: CHEUNG, Culver; c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US).

nia 94063 (US). **DOUGLAS, Mark**; c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US). **LILLIE, James**; c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US). **WOOD, Michael**; c/o MapLight Therapeutics, Inc., 800 Chesapeake Drive, Redwood City, California 94063 (US).

(74) Agent: TUSCAN, Michael et al.; Cooley LLP, 1299 Pennsylvania Ave., NW, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) Title: COMPOSITIONS FOR TREATING NEUROLOGICAL DISORDERS




FIG. 15

(57) Abstract: Combination compositions of Compound 1 and fesoterodine for treating a neurological disorder (such as schizophrenia, Alzheimer's disease psychosis, Parkinson's Disease Psychosis, cognition in Alzheimer's disease, psychosis in dementia with Lewy bodies, bipolar disorders and dyskinesias) are described.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(88) Date of publication of the international search report:

26 December 2024 (26.12.2024)